CMS proposes electronic prior authorization for drugs in health plans
CMS has proposed a new rule that would expand electronic prior authorization to drugs and add faster decision timelines for some plans. The change is not final yet, and the details could still change after public comment closes on June 15, 2026.
CMS has proposed a new rule that would expand electronic prior authorization to drugs and add new transparency requirements for some health plans. For many readers, the practical takeaway is simple: if finalized, the change could mean faster decisions and less paperwork, but it would not make prior authorization disappear.
The rule is still proposed, not final. CMS is taking public comments through June 15, 2026, and the implementation timeline could still change after that review.
What CMS proposed
In April 2026, CMS said it wants affected payers to support electronic prior authorization for drugs, along with updates to health IT standards and reporting on API endpoints and usage. CMS also proposed shorter turnaround times for some drug-related prior authorization decisions and more transparency around the process.
CMS said the proposal would build on its earlier interoperability rules and extend similar electronic workflows to drug coverage. The agency says the goal is to reduce delays, standardize information exchange, and make it easier for plans and providers to move requests through digitally rather than by fax or other manual methods.
Who would be covered
CMS said the proposal would apply to Medicare Advantage plans, Medicaid fee-for-service programs, Medicaid managed care plans, CHIP managed care entities, and Qualified Health Plan issuers on the federal exchanges. CMS also proposed adding small-group market QHP issuers offering plans through the federal Small Business Health Options Program.
The proposal would reach both medical-benefit drugs and, for certain programs, pharmacy-benefit drugs. But the exact impact will still depend on the final rule, the plan, and how a given payer chooses to implement the required systems.
What is already in motion
This is not CMS’s first step on prior authorization. In the 2024 final rule, CMS already set prior authorization API requirements for non-drug items and services, with major compliance dates generally beginning in 2027. CMS also continues to describe January 1, 2027, as the start date for certain API requirements under its broader electronic prior authorization work.
That matters because the 2026 proposal is meant to build on an existing framework, not replace it. In other words, some of the technology and workflow changes are already underway, and the drug-specific proposal would extend those systems further.
Why it matters for patients and providers
For patients, faster electronic processing could reduce delays when a drug needs approval before it can be filled or covered. For clinicians and offices, it could reduce the time spent chasing paperwork and checking plan requirements.
Still, a faster digital process does not guarantee a uniform experience. Prior authorization rules can vary by plan, state program, benefit design, and drug type, and some requests may still need more information before a decision is made.
What happens next
CMS is accepting public comments until June 15, 2026. After that, the agency will review comments, decide whether to revise the proposal, and then issue a final rule if it moves forward.
If the rule is finalized, the details will matter: which plans are covered, which data standards are required, and how quickly plans must be ready. For now, readers should treat this as a significant policy proposal, not a finished change.
What readers can do
If you get coverage through Medicare Advantage, Medicaid, CHIP, or an ACA marketplace plan, keep an eye on plan notices and updates from CMS. If a medication is delayed now, do not assume this proposal will change your current coverage immediately.
It can still help to ask a plan or provider office how prior authorization requests are handled, whether electronic submission is available, and what information is usually needed to avoid delays.
Sources
Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.
This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.
